Esperion Therapeutics, Inc. (ESPR) Stock Price Up 6.8%
Esperion Therapeutics, Inc. (NASDAQ:ESPR)’s share price rose 6.8% during trading on Friday . The company traded as high as $52.95 and last traded at $52.77, with a volume of 872,916 shares traded. The stock had previously closed at $49.42.
ESPR has been the topic of a number of analyst reports. ValuEngine raised Esperion Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. Zacks Investment Research upgraded Esperion Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, May 9th. Deutsche Bank AG assumed coverage on Esperion Therapeutics in a research report on Friday, June 23rd. They issued a “buy” rating and a $48.00 price objective on the stock. BidaskClub lowered Esperion Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Friday, August 4th. Finally, Citigroup Inc. reiterated a “buy” rating on shares of Esperion Therapeutics in a research report on Thursday, June 22nd. Seven research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Esperion Therapeutics has a consensus rating of “Buy” and an average price target of $51.65.
The firm’s 50 day moving average is $47.50 and its 200-day moving average is $38.67. The stock’s market cap is $1.19 billion.
Esperion Therapeutics (NASDAQ:ESPR) last issued its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.92) earnings per share for the quarter, missing the consensus estimate of ($1.67) by $0.25. During the same period in the previous year, the firm posted ($0.62) earnings per share. Equities research analysts predict that Esperion Therapeutics, Inc. will post ($7.33) EPS for the current fiscal year.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ESPR. Lord Abbett & CO. LLC purchased a new position in Esperion Therapeutics during the second quarter valued at approximately $6,432,000. Tower Research Capital LLC TRC increased its position in Esperion Therapeutics by 69,371.4% in the second quarter. Tower Research Capital LLC TRC now owns 4,863 shares of the biopharmaceutical company’s stock valued at $225,000 after buying an additional 4,856 shares during the last quarter. RA Capital Management LLC increased its position in Esperion Therapeutics by 3.8% in the second quarter. RA Capital Management LLC now owns 731,531 shares of the biopharmaceutical company’s stock valued at $33,855,000 after buying an additional 26,830 shares during the last quarter. State Street Corp increased its position in Esperion Therapeutics by 264.6% in the second quarter. State Street Corp now owns 1,506,514 shares of the biopharmaceutical company’s stock valued at $69,721,000 after buying an additional 1,093,292 shares during the last quarter. Finally, Macquarie Group Ltd. purchased a new position in Esperion Therapeutics during the second quarter valued at approximately $1,182,000. Institutional investors own 83.33% of the company’s stock.
WARNING: This story was posted by Daily Political and is the sole property of of Daily Political. If you are viewing this story on another domain, it was stolen and reposted in violation of United States and international trademark and copyright laws. The original version of this story can be accessed at https://www.dailypolitical.com/2017/09/03/esperion-therapeutics-inc-espr-stock-price-up-6-8.html.
Esperion Therapeutics Company Profile
Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.